Hiroyuki Yamaguchi

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto et al. · The Lancet Oncology · 2019 · 594 citations · Full text

Medicine, Pathology, Immune Checkpoint Inhibitor +5

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells

Hirokazu Taniguchi, Tadaaki Yamada, Rong Wang et al. · Nature Communications · 2019 · 351 citations · Full text

Genomic characterization of primary central nervous system lymphoma

Kazutaka Fukumura, Masahito Kawazu, Shinya Kojima et al. · Acta Neuropathologica · 2016 · 180 citations

Neuro-oncology, Lymphoid Neoplasia, Pathology +4

Role of disseminated intravascular coagulation in severe sepsis

Satoshi Gando, Atsushi Shiraishi, Kazuma Yamakawa et al. · Thrombosis Research · 2019 · 132 citations

Inflammation, Thrombosis, Severe Sepsis +6

Transforming mutations of RAC guanosine triphosphatases in human cancers

Masahito Kawazu, Toshihide Ueno, Kenji Kontani et al. · Proceedings of the National Academy of Sciences · 2013 · 122 citations · Full text

Signal Transduction, Cell Regulation, Oncogenic Agent +13